The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
Long-term follow up of patients with extensive stage small cell lung cancer who were given pembrolizumab and etoposide/platinum (EP) versus placebo + etoposide/platinum as first-line therapy support the continued exploration ...
Aug 9, 2022
0
7
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy ...
Aug 8, 2022
0
2
Results of an international clinical trial co-led by researchers at Winship Cancer Institute at Emory University show potential for a novel drug to benefit patients with multiple myeloma whose disease either recurred or was ...
Aug 3, 2022
0
1509
A team of researchers at the University of Minnesota Medical School has looked into the question of why most people do not develop an immune response after consuming food. In their paper published in the journal Nature, the ...
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found ...
Jul 11, 2022
0
6
Patients with advanced kidney cancer who received a new combination treatment reported health-related quality of life outcomes that were either similar or improved, compared to patients who received standard first-line therapy, ...
Jun 24, 2022
0
80
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells. Using ...
Jun 13, 2022
0
28
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
